How much does trametinib cost per month? A complete guide to prices and medical insurance reimbursement

Trametinib/Megenin (Trametinib) As a highly selectiveMEK1/2 inhibitor, it is mainly used to treat patients with BRAF Tumor types such as unresectable or metastatic melanoma, thyroid cancer, and non-small cell lung cancer with V600E or V600K mutations are usually combined with the BRAF inhibitor dabrafenib to enhance efficacy and delay the occurrence of drug resistance. In treatment, the standard recommended dose for adults is 2 mg orally once daily. It does not need to be taken with food. Patients should take it on an empty stomach to ensure maximum bioavailability of the drug.

Regarding costs, the original drug trametinib has been launched in mainland China and has been included in the medical insurance catalog, but the medical insurance reimbursement conditions are limited to patients diagnosed as meeting the indications. The common specifications on the market are 2mg×30 tablets/box, and the price is approximately RMB 10,000. If the patient does not have medical insurance support, based on the recommended dose of 2 mg per day, the cost of treatment for a month is about 10,000 yuan, which falls into the category of high-priced targeted drugs. However, after medical insurance is reimbursed, patients can bear the actual expenses themselves according to the specific reimbursement ratio (e.g., ranging from 70% to 85%). The reimbursement ratio varies depending on regional policies and patient insurance types.

In addition, some countries such as Laos or Bangladesh have also begun to produce generic versions of trametinib. The ingredients are basically the same as the original drug. However, because they are not marketed through China, they can only be obtained through overseas channels. The monthly cost of these generic drugs is about 1,000-2,000 yuan, which is very price-advantageous and is especially suitable for patient groups with high financial pressure. However, it is recommended to strictly evaluate the legality of the source and drug quality assurance before use.

It needs to be particularly emphasized that trametinib is a high-risk targeted drug, and the treatment process should be guided by a professional oncologist, and the BRAF mutation status needs to be determined before treatment Some patients may experience adverse reactions such as rash, decreased cardiac function, blurred vision, etc. Therefore, regular monitoring of cardiac function and fundus examination is required to ensure the safety and long-term efficacy of treatment.

Reference materials:https://go.drugbank.com/drugs/DB08911